In small-animal antihistamine tablet manufacturing, chlorphenamine maleate is incorporated at a nominal 4 mg per tablet for canine pruritus and 2–4 mg per tablet for feline use, with the active pharmaceutical ingredient fraction at 2.0% w/w in a 200 mg core. The API must conform to Ph. Eur. 0386 and USP Chlorpheniramine Maleate, with assay on dried basis 98.0–102.0% and related substances not more than 0.5%. The finished tablet must meet USP <905> or Ph. Eur. 2.9.40 uniformity of dosage units with an acceptance value not greater than 15.0, and dissolution per USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 M hydrochloric acid at 37±0.5°C; a typical premarketing specification is Q=80% at 30 min. The tablet core comprises microcrystalline cellulose 45–55% w/w, anhydrous lactose 30–40% w/w, crospovidone 2–4% w/w, colloidal silicon dioxide 0.5–1.0% w/w, and magnesium stearate 0.5–1.0% w/w. Wet granulation is preferred over direct compression when the chlorphenamine maleate source is micronized with a D90 below 75 µm because low-dose blend segregation has been observed in bin blenders at 12 rpm when API particle size D50 drops below 10 µm.

The aqueous granulation binder is hypromellose 3 mPa·s at 1.5–2.5% w/w, added in a top-drive high-shear granulator at impeller tip speed 5–8 m/s; wet massing is held to 2–4 min. The granulate is dried in a fluid-bed dryer with inlet air at 60–70°C and product temperature 35–40°C to a loss-on-drying window of 1.5–3.0% w/w; batches with LOD below 1.5% w/w show increased capping on 27-station rotary tablet presses, while LOD above 3.0% w/w produces sticking to B2/D2 tooling at main compression above 15 kN. The dried granulate is passed through a 0.8 mm oscillating sieve, lubricated in a V-blender at 60% volumetric fill for 5 min, and compressed with precompression 3–6 kN and main compression 8–15 kN to 50–80 N hardness. Tablet friability must be not more than 1.0% per USP <1216>, and package light transmission is controlled per USP <671> because chlorphenamine maleate photodegradation accelerates in non-amber packaging. Terminal dosage forms are round, single-scored biconvex tablets in 60 cc HDPE bottles with a 2 g silica-gel desiccant, or in PVC/PVDC blister. A known process conflict is that magnesium stearate levels above 1.0% w/w slow dissolution to below 80% at 30 min due to hydrophobic film formation on the granules; therefore, lubrication time is capped at 5 min and the stearate is screened through 500 µm before use.

What Limits Sterile Filtration Throughput in Chlorphenamine Maleate Injection Solutions?

Sterile filtration of a 10 mg/mL chlorphenamine maleate injection is governed by the pH-dependent equilibrium between the water-soluble maleate salt and the poorly water-soluble free base; the solution is buffered to pH 5.0–5.5 with 0.1 M hydrochloric acid or sodium hydroxide, because above pH 6.5 free base precipitation reduces filter flux and raises subvisible particle counts. The formulation consists of chlorphenamine maleate 10 mg/mL, sodium chloride 9.0 mg/mL, water for injection q.s., and, if a multidose presentation is selected, benzyl alcohol 1.5% v/v; single-use vials omit the preservative but require a nitrogen overlay during filling. The solution is compounded in a 316L stainless steel jacketed vessel at 20–25°C, protected from light, and sparged with nitrogen to reduce dissolved oxygen below 0.5 mg/L. A 0.45 µm polypropylene prefiltration cartridge is followed by a 0.22 µm PVDF or PES sterilizing-grade membrane with a filter area of not less than 0.5 m² per 200 L batch; pressure differential is maintained below 1.0 bar because chlorphenamine maleate solutions above 25°C accelerate N-oxide degradation and can foul downstream membranes.

Industry compliance for this injectable line includes 21 CFR 210/211, USP <1>, USP <85>, USP <788>, USP <1207>, Ph. Eur. 5.1.1, and EU GMP Annex 1 with ISO 14644-1 Class 5 filling. Bacterial endotoxins are controlled per USP <85>; because the maximum bolus dose in equine practice can be 250 mg, the endotoxin limit is calculated from the 5 EU/kg/h parenteral threshold and the batch must typically meet an API endotoxin limit of not more than 0.5 EU/mg. Sterility testing follows USP <71> or Ph. Eur. 2.6.1 with 14-day incubation; container closure integrity is verified by vacuum decay per USP <1207>. Terminal sterilization by steam is not automatically feasible because the maleate salt can undergo hydrolytic degradation above 121°C; aseptic filtration is therefore the standard process, and any terminal sterilization program requires photostability and thermal stability data under ICH Q1B and ICH Q1A. The terminal product is filled into amber Type I borosilicate glass vials of 10 mL or 50 mL, closed with chlorobutyl rubber stoppers and aluminium flip-off seals. A known production failure mode occurs when line stoppages exceed 90 min between prefiltration and final filtration: microbial proliferation in the intermediate bulk can elevate bioburden above 10 CFU/100 mL and require batch reprocessing or rejection.

Because feline dosing frequently requires volumes below 0.5 mL, chlorphenamine maleate oral solution is manufactured at 0.4 mg/mL (2 mg/5 mL) with a target dose of 2 mg per cat every 12 h. The solution uses purified water as basis, sorbitol 70% non-crystallizing at 20–30% w/v, glycerin 10–20% w/v, citric acid–sodium citrate buffer to hold pH 4.5–5.5, sodium benzoate 0.1% w/v or potassium sorbate 0.15% w/v, and sucralose 0.05% w/v. The manufacturing sequence includes high-shear mixing at 1,800–2,500 rpm for 15 min to dissolve the API, pH adjustment with 0.1 N citric acid, and clarification through 1.2 µm followed by 0.45 µm polypropylene filters; the filtered bulk is held under nitrogen pressure below 0.5 bar until filling. Filling is performed on a 12-head volumetric liquid filler into amber PET bottles of 100 mL, with an in-process fill weight check every 15 min per 21 CFR 211.184. Compliance references include USP <795> for hospital dilution, VICH GL18 residual solvent testing, ICH Q3D elemental impurity limits, and USP <1231> water quality. Light stability under ICH Q1B is mandatory because aqueous chlorphenamine maleate forms N-oxide photodegradants; amber packaging and cartons are specified. The terminal dosage form is a 2 mg/5 mL oral solution with a graduated dropper calibrated to deliver 0.1 mL increments; batch release includes assay 95.0–105.0% of label claim, pH 4.5–5.5, preservative efficacy per USP <51>, and microbial limits of not more than 100 CFU/mL total aerobic microbial count and not more than 10 CFU/mL total yeast and mold count.

Granule Density, Dusting, and Dose Uniformity Constraints in Equine Top-Dress Powders

Equine top-dress granules containing chlorphenamine maleate are formulated at 1.25% w/w API to deliver 125 mg chlorphenamine maleate in a 10 g dose cup for a 500 kg horse at 0.25 mg/kg body weight. The carrier system is a dibasic calcium phosphate–lactose composite 85–92% w/w, povidone K30 2–4% w/w as a wet binder, and microcrystalline cellulose 5–10% w/w as a spheronization aid. The addition ratio is restricted to a maximum of 2.0% w/w because higher API loading reduces granule flow to below 10 g/s through a 15 mm orifice and increases dusting below 45 µm; dusting is limited to not more than 15% w/w of the granulation and measured by sieve analysis per USP <786> or Ph. Eur. 2.9.38. The process runs in a top-drive high-shear granulator at an impeller tip speed of 5–8 m/s, with the binder solution added at 8–12% w/w and wet massing held at 2–4 min. Drying in a fluid-bed unit at 60–70°C inlet air to a final loss on drying of 1.5–2.5% w/w is followed by size classification over 0.5 mm and 1.0 mm sieves; granule D50 is controlled at 150–250 µm.

Compliance for this non-sterile oral powder product is anchored to 21 CFR 210/211, EU GMP Part I, VICH GL18 for residual solvents, and USP <905> blend uniformity with a stratified sampling plan across at least 10 locations; blend coefficient of variation should not exceed 5.0%. The terminal product is filled into 10 g graduated dosing cups or three-side-sealed sachets, with net weight variation not more than ±5% and water activity below 0.60. For operators, chlorphenamine maleate is an antihistamine with anticholinergic effects; engineering controls must limit airborne dust to the OEL established in the site hygienic plan, and ISO 14644-1 Class D is normally sufficient for product protection because the dosage form is not sterile. A notable process boundary is that ambient relative humidity above 60% during granulation and filling increases moisture uptake in the lactose carrier, raises granule stickiness, and generates 0.5–2.0 mm agglomerates that can cause dose cup weight variability. Published multi-batch process capability data for chlorphenamine maleate at this specific 1.25% w/w equine granule loading is limited; therefore, process validation typically uses a 3-batch homoscedasticity check rather than a compressed historical parameter range.

When Hard Gelatin Capsules Are Selected Over Tablets for Low-Dose Feline Administration

Because the labeled dose is 2 mg chlorphenamine maleate for cats and tablet splitting is considered inaccurate for home administration, hard gelatin capsule manufacture is selected; the capsule fill mass is 90 mg in a size 4 hard gelatin or hydroxypropyl methylcellulose capsule, giving an API fraction of 2.2% w/w. Direct filling is feasible only if the API is preblended in a 1:10 geometric dilution with lactose monohydrate for 10 min at 12 rpm in a bin blender; the preblend is then passed through a 500 µm screen before final blending at 60% volumetric fill for 15 min. Magnesium stearate is limited to 0.25–0.5% w/w and talc to 1–2% w/w; exceeding 0.5% stearate delays disintegration beyond 15 min in 0.1 M hydrochloric acid. Filling is performed on a dosator-type automatic encapsulator at 25,000–40,000 capsules/h with fill weight checks every 15 min; the weight variation standard is USP <905> or Ph. Eur. 2.9.40 with acceptance value not greater than 15.0. Dissolution testing uses USP <711> Apparatus I at 100 rpm in 900 mL of 0.1 M hydrochloric acid with Q=80% at 30 min. Compliance includes 21 CFR 211, ICH Q1A stability, ICH Q3D elemental impurities, and USP <61>/<62> microbial limits. Because capsules are moisture-sensitive, aluminium/PVC cold-form blister packaging is preferred over bottles, with USP <671> light-transmission containers. Terminal product is a 2 mg hard gelatin capsule in aluminium/PVC cold-form blister, stored below 25°C. A documented low-dose production issue is electrostatic adhesion of micronized chlorphenamine maleate to the walls of the bin blender after the geometric dilution step; if blender humidity drops below 30% RH, API recovery can fall below 95% of label claim, requiring post-blend API assay before encapsulation.

Premix Dilution Ratios and Cross-Contamination Controls in Hospital Feed Preparation

In hospital feed preparation, a non-sterile oral premix intermediate containing chlorphenamine maleate at 5.0% w/w is incorporated at 0.1% w/w of final feed, equivalent to 1 kg premix per 1,000 kg feed, to yield 50 mg/kg API in feed and deliver 125 mg chlorphenamine maleate per 2.5 kg feed for a 500 kg horse at 0.25 mg/kg. The carrier is ground oat hulls or maltodextrin 80–90% w/w, with silicon dioxide 1–2% w/w as flow aid and corn starch 5–10% w/w as dust binder. Mixing uses a double-cone blender at 60% volumetric fill and 10 rpm for 20 min; a geometric dilution sequence in three steps is required because the API is active at 5% while the final feed concentration is only 0.005% w/w. Homogeneity is assessed by sampling at 10 locations with a coefficient of variation not more than 5.0% for the premix and not more than 10% for the diluted feed.

Regulatory status varies by jurisdiction: under EU Regulation (EU) 2019/4 on medicated feed, equidae are food-producing unless permanently excluded from the food chain, so the horse’s non-food status must be documented and the premix must not enter supply chains for food-producing species. In the United States, 21 CFR 225 current good manufacturing practice for medicated feed applies if the premix is used in a commercial feed mill; hospital extemporaneous dilution may instead fall under USP <795>. Cross-contamination control is the primary operational risk: because chlorphenamine maleate is a pharmacologically active antihistamine, dedicated scoops and dust extraction are used, and cleaning validation is performed with swab limits derived from a health-based exposure assessment per EMA guidance rather than a fixed visual-clean criterion. Published residue data for chlorphenamine maleate in feed premix equipment is limited; therefore, a conservative default cleaning limit of 1 µg/cm² is often applied until a product-specific permitted daily exposure is calculated. Terminal packaging is 1 kg foil-lined HDPE jars or 5 kg aluminium foil bags with desiccant, stored below 25°C and protected from light. The premix is not sterile, not suitable for parenteral use, and not authorized in several jurisdictions for food-producing animal feed.